Inventor · disambiguated record
Drew M. Pardoll
Also filed as: PARDOLL DREW · PARDOLL DREW M
53 granted patents·40 pending applications·1,505 citations·filing 1993–2024
99Inventor score
Files withUNIV JOHNS HOPKINS66UNIV JOHNS HOPKINS MED6PARDOLL DREW M3UNIV SOUTH FLORIDA3PARDOLL DREW2
Top patents by PatentIndex Score
93 records- 0197US11634491B2Checkpoint blockade and microsatellite instabilityUNIV JOHNS HOPKINS·Filed 2022·Granted Apr 25, 2023·2 cites·38 claims
- 0297US11591393B2Checkpoint blockade and microsatellite instabilityUNIV JOHNS HOPKINS·Filed 2021·Granted Feb 28, 2023·4 cites·42 claims
- 0397US11339219B2Checkpoint blockade and microsatellite instabilityUNIV JOHNS HOPKINS·Filed 2020·Granted May 24, 2022·10 cites·8 claims
- 0497US11325975B2Checkpoint blockade and microsatellite instabilityUNIV JOHNS HOPKINS·Filed 2020·Granted May 10, 2022·8 cites·15 claims
- 0597US11325974B2Checkpoint blockade and microsatellite instabilityUNIV JOHNS HOPKINS·Filed 2020·Granted May 10, 2022·10 cites·7 claims
- 0697US9770467B2Compositions and methods for cancer immunotherapyUNIV JOHNS HOPKINS·Filed 2013·Granted Sep 26, 2017·31 cites·9 claims
- 0796US11643462B2Checkpoint blockade and microsatellite instabilityUNIV JOHNS HOPKINS·Filed 2021·Granted May 9, 2023·2 cites·30 claims
- 0896US11629187B2Checkpoint blockade and microsatellite instabilityUNIV JOHNS HOPKINS·Filed 2021·Granted Apr 18, 2023·2 cites·28 claims
- 0996US10934356B2Checkpoint blockade and microsatellite instabilityUNIV JOHNS HOPKINS·Filed 2018·Granted Mar 2, 2021·15 cites·28 claims
- 1096US9005629B2Method for treating cancer with an antibody to CD223 proteinUNIV JOHNS HOPKINS·Filed 2012·Granted Apr 14, 2015·42 cites·4 claims
- 1195US8053414B2Methods of using B7-DC molecules to induce or enhance an immune responseUNIV JOHNS HOPKINS·Filed 2007·Granted Nov 8, 2011·29 cites·45 claims
- 1295US8053558B2Dendritic cell co-stimulatory moleculesUNIV JOHNS HOPKINS·Filed 2007·Granted Nov 8, 2011·29 cites·31 claims
- 1395US7560540B2Nucleic acid encoding dendritic cell co-stimulatory moleculesUNIV JOHNS HOPKINS·Filed 2006·Granted Jul 14, 2009·50 cites·15 claims
- 1494US9308253B2Cancer immunotherapyUNIV JOHNS HOPKINS·Filed 2012·Granted Apr 12, 2016·21 cites·27 claims
- 1594US9132281B2Focused radiation for augmenting immune-based therapies against neoplasmsZENG JING·Filed 2012·Granted Sep 15, 2015·68 cites·16 claims
- 1694US7030219B2B7-DC, Dendritic cell co-stimulatory moleculesUNIV JOHNS HOPKINS·Filed 2001·Granted Apr 18, 2006·51 cites·38 claims
- 1794US5904920ARegulation of systemic immune responses utilizing cytokines and antigensWHITEHEAD BIOMEDICAL INST·Filed 1995·Granted May 18, 1999·123 cites·9 claims
- 1893US8551481B2Anti-cancer vaccine composition comprising an anti-CD223 antibody and kit comprising an anti-cancer vaccine and an anti-CD223 antibodyPARDOLL DREW M·Filed 2009·Granted Oct 8, 2013·41 cites·6 claims
- 1992US5637483AIrradiated tumor cell vaccine engineered to express GM-CSFWHITEHEAD BIOMEDICAL INST·Filed 1994·Granted Jun 10, 1997·169 cites·17 claims
- 2091US7638122B2Stat3 antagonists and their use as vaccines against cancerUNIV SOUTH FLORIDA·Filed 2003·Granted Dec 29, 2009·41 cites·12 claims
- 2191US5633234ALysosomal targeting of immunogensUNIV JOHNS HOPKINS·Filed 1993·Granted May 27, 1997·146 cites·20 claims
- 2290US6268411B1Use of multivalent chimeric peptide-loaded, MHC/ig molecules to detect, activate or suppress antigen-specific T cell-dependent immune responsesUNIV JOHNS HOPKINS·Filed 1998·Granted Jul 31, 2001·95 cites·104 claims
- 2390US6033674AMethod of treating cancer with a tumor cell line having modified cytokine expressionUNIV JOHNS HOPKINS MED·Filed 1996·Granted Mar 7, 2000·83 cites·17 claims
- 2489US6350445B1Method of treating cancer with a tumor cell line having modified cytokine expressionUNIV JOHNS HOPKINS MED·Filed 1999·Granted Feb 26, 2002·78 cites·17 claims
- 2589US5985290APurified pancreatic tumor cell lines and related compositions and methodUNIV JOHNS HOPKINS MED·Filed 1998·Granted Nov 16, 1999·69 cites·17 claims
- 2689US2023365677A1Checkpoint blockade and microsatellite instabilityUNIV JOHNS HOPKINS·Filed 2023·Application pending·0 cites
- 2788US7767202B2Modulation of systemic immune responses by transplantation of hematopoietic stem cells transduced with genes encoding antigens and antigen presenting cell regulatory moleculesUNIV JOHNS HOPKINS·Filed 2002·Granted Aug 3, 2010·46 cites·18 claims
- 2888US6734013B2Use of multivalent chimeric peptide-loaded, MHC/Ig molecules to detect, activate or suppress antigen-specific T cell-dependent immune responsesUNIV JOHNS HOPKINS·Filed 2001·Granted May 11, 2004·27 cites·4 claims
- 2987US5861159AControlled release of pharmaceutically active substances for immunotherapyUNIV JOHNS HOPKINS MED·Filed 1996·Granted Jan 19, 1999·94 cites·13 claims
- 3085US11753468B2Checkpoint blockade and microsatellite instabilityUNIV JOHNS HOPKINS·Filed 2022·Granted Sep 12, 2023·0 cites·26 claims
- 3184US11718668B2Checkpoint blockade and microsatellite instabilityUNIV JOHNS HOPKINS·Filed 2022·Granted Aug 8, 2023·0 cites·30 claims
- 3284US10864180B2Combination of immunotherapy with local chemotherapy for the treatment of malignanciesUNIV JOHNS HOPKINS·Filed 2016·Granted Dec 15, 2020·2 cites·9 claims
- 3384US2024174747A1T cell regulationUNIV JOHNS HOPKINS·Filed 2023·Application pending·0 cites
- 3481US11649287B2Checkpoint blockade and microsatellite instabilityUNIV JOHNS HOPKINS·Filed 2021·Granted May 16, 2023·0 cites·36 claims
- 3580US9523126B2Compositions and methods for modulating an immune responseUNIV JOHNS HOPKINS·Filed 2014·Granted Dec 20, 2016·3 cites·6 claims
- 3680US7951374B2Methods for inhibiting STAT3 signaling in immune cellsUNIV SOUTH FLORIDA·Filed 2005·Granted May 31, 2011·1 cites·14 claims
- 3779US10787513B2Methods for treatment comprising an antibody that binds CD223 proteinUNIV JOHNS HOPKINS·Filed 2015·Granted Sep 29, 2020·1 cites·25 claims
- 3878US6193970B1Controlled release of pharmaceutically active substances for immunotherapyUNIV JOHNS HOPKINS MED·Filed 1998·Granted Feb 27, 2001·58 cites·27 claims
- 3978US6187306B1Melanoma cell lines expressing shared immunodominant melanoma antigens and methods of using sameUNIV JOHNS HOPKINS·Filed 1997·Granted Feb 13, 2001·51 cites·17 claims
- 4077US11236156B2Compositions and methods for targeting activin signaling to treat cancerUNIV JOHNS HOPKINS·Filed 2017·Granted Feb 1, 2022·1 cites·7 claims
- 4176US2023414540A1Combination of immunotherapy with local chemotherapy for the treatment of malignanciesUNIV JOHNS HOPKINS·Filed 2023·Application pending·0 cites
- 4276US2025032677A1Compositions and methods for modulating wound healing and regenerationUNIV JOHNS HOPKINS·Filed 2024·Application pending·0 cites
- 4374US11478548B2Marrow infiltrating lymphocytes (MILs) as a source of T-cells for chimeric antigen receptor (CAR) therapyUNIV JOHNS HOPKINS·Filed 2016·Granted Oct 25, 2022·1 cites·8 claims
- 4474US2021230275A1T cell regulationUNIV JOHNS HOPKINS·Filed 2021·Application pending·0 cites
- 4572US10934354B2Methods of increasing T cell immune response in the treatment of cancerUNIV JOHNS HOPKINS·Filed 2018·Granted Mar 2, 2021·0 cites·20 claims
- 4671US12312398B2Compositions and methods for targeting activin signaling to treat cancerUNIV JOHNS HOPKINS·Filed 2021·Granted May 27, 2025·0 cites·10 claims
- 4771US2023210990A1Marrow infiltrating lymphocytes (mils) as a source of t-cells for chimeric antigen receptor (car) thereapyUNIV JOHNS HOPKINS·Filed 2022·Application pending·0 cites
- 4871US2023248884A1Compositions and methods for modulating wound healing and regenerationUNIV JOHNS HOPKINS·Filed 2022·Application pending·0 cites
- 4970US2025161371A1Regenerative helminth containing compositions and uses thereofUNIV JOHNS HOPKINS·Filed 2024·Application pending·0 cites
- 5070US2023016031A1Marrow infiltrating lymphocytes (mils) as a source of t-cells for chimeric antigen receptor (car) thereapyUNIV JOHNS HOPKINS·Filed 2022·Application pending·0 cites
Showing the top 50 of 93 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Drew M. Pardoll files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →